DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



Business Affairs Homepage

Siemens Healthineers shares surge after Frankfurt Stock Exchange IPO The stock closed at 30 euros on Friday

FDA warns duodenoscope makers about failure to comply with requirements Reprocessing issues resurface for Olympus, Fujifilm and Pentax

Cigna to purchase Express Scripts for $52 billion The latest in a string of insurance-pharma M&A activity

Onkos Surgical and 3D Systems sign four-year business agreement Personalizing musculoskeletal cancer treatment

Samsung and Philips partner to broaden the connected health ecosystems The companies' platforms will be connected

Canon acquires cardiac IT manufacturer Fysicon Obtains wide portfolio of monitoring systems sold globally

Verasonics files suit against Supersonic Imagine Claims software beamforming architecture infringes patent

Northwell Health touts Philips collab for ICU and ED improvements at HIMSS Experienced 20 percent drop in ICU mortality rate

Philips inks deal with Hologic for mammography equipment Will integrate with broader portfolio for 'a complete set of innovative diagnostic imaging systems'

Siemens now planning smaller Healthineers IPO The offer puts a price of 31 billion euros on the division, previously estimated around 35 billion

Absorb dissolvable stent shows higher cardio risk in some cases, FDA warns

by Thomas Dworetzky , Contributing Reporter
New concerns about the Absorb bioresorbable scaffold stent have come to light in two-year results of the ABSORB III trial, researchers reported at a clinical trials session at the American College of Cardiology’s 66th Annual Scientific Session, March 18.

“Patients receiving Absorb BVS faced an overall elevated risk of adverse outcomes at two years compared with patients receiving metal stents, a difference that appears to be attributable to the stent being placed in vessels that were smaller than recommended,” Absorb-maker Abbott said in a statement.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

The FDA has sent a letter about the issue to cardiologists and health care providers. The agency stated to those treating patients with the Absorb GT1 Bioresorbable Vascular Scaffold (BVS) that there is “an increased rate of major adverse cardiac events observed in patients receiving the BVS, when compared to patients treated with the approved, metallic XIENCE drug-eluting stent.”

It specified that the findings showed “an 11 percent rate of major adverse cardiac events (e.g., cardiac death, heart attack, or the need for an additional procedure to reopen the treated heart vessel) in patients treated with the BVS at two years, compared with 7.9 percent in patients treated with the already-approved Abbott Vascular's metallic Xience drug-eluting stent,” noting, in addition, that the review also found “a 1.9 percent rate of developing blood clots within the BVS versus 0.8 percent within the Xience stent at 2 years.”

The FDA's guidelines advised “avoiding its use in small vessels.”

Cleveland Clinic cardiologist and the study's lead author Dr. Stephen Ellis called small-vessel avoidance a “key take-home” in the Abbott statement, adding that, "this isn't necessarily surprising, because the Absorb BVS is considerably larger than the Xience stent, but it would have been preferable to have more consistency with regard to the vessel sizing and utilization of the device in the study."

One-year results had shown absorbable stents were “non-inferior” compared with metal ones “as measured by a composite of cardiac death, target lesion heart attack and ischemia-driven target lesion revascularization.”

This changed between year one and two, however, as the latest report showed, according to Abbott. These new results demonstrated “that at the end of year two, patients receiving Absorb BVS showed a significantly higher risk of target lesion failure,” although there were some “inconsistencies with regard to adherence to study protocols and the procedural techniques used to place the device” that may have led to some of the adverse outcomes.
  Pages: 1 - 2 >>

Business Affairs Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.